Modeling Human Myocardium Exposure to Doxorubicin Defines the Risk of Heart Failure from Low-Dose Doxorubicin
Open Access
- 1 August 2017
- journal article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 362 (2) , 263-270
Abstract
The antitumor anthracycline, doxorubicin (DOX), can cause heart failure (HF) upon cumulative administration. Lowering the cumulative dose of DOX proved useful to minimize HF risk, and, yet, there is a growing concern that HF might occur after doses that were thought to be safe. Clinical trials that prospectively address such concerns are lacking. Because HF risk correlates with cardiac exposure to DOX, cumulative doses associated with HF risk were re-explored by modeling the accumulation of anthracycline pools in human myocardium. Ex vivo myocardial samples were used in vitro to simulate DOX rapid infusions. The accumulation of anthracycline pools was measured and incorporated into equations from which a risk versus dose curve was obtained. The experimental curve identified a 5% risk dose that was congruent with a previously reported clinical value (380 versus 400 mg/m2, respectively); however, 1–2% risk occurred after lower doses than reported. Simulations of gain-of-function polymorphism of carbonyl reductase 3, which converts DOX to its poorly diffusible alcohol metabolite, doxorubicinol (DOXOL), expanded anthracycline pools and caused 5% or 1–2% risk doses to decrease to 330 or 180–230 mg DOX/m2, respectively. These data show there is no safe dose of DOX. Diminishing cardiac exposure to circulating DOX may represent a cardioprotective strategy. We show that DOX slow infusions or liposomal DOX, which reduce cardiac exposure to DOX, caused formation of smaller anthracycline pools, did not generate DOXOL, increased the 5% risk dose to 750–800 mg/m2, and prevented HF risk aggravation by carbonyl reductase polymorphism.Keywords
This publication has 27 references indexed in Scilit:
- Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure TherapyCirculation, 2015
- Low to Moderate Dose Anthracycline-Based Chemotherapy Is Associated With Early Noninvasive Imaging Evidence of Subclinical Cardiovascular DiseaseJACC: Cardiovascular Imaging, 2013
- Continuous Versus Bolus Infusion of Doxorubicin in Children With ALL: Long-term Cardiac OutcomesPediatrics, 2012
- Anthracycline-Related Cardiomyopathy After Childhood Cancer: Role of Polymorphisms in Carbonyl Reductase Genes—A Report From the Children's Oncology GroupJournal of Clinical Oncology, 2012
- Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline‐related congestive heart failure after childhood cancerCancer, 2008
- FUNCTIONAL SIGNIFICANCE OF A NATURAL ALLELIC VARIANT OF HUMAN CARBONYL REDUCTASE 3 (CBR3)Drug Metabolism and Disposition, 2005
- Early cardiotoxicity of the CHOP regimen in aggressivenon-Hodgkin’s lymphomaAnnals of Oncology, 2003
- A Mathematical Model for Comparison of Bolus Injection, Continuous Infusion, and Liposomal Delivery of Doxorubicin to Tumor CellsNeoplasia, 2000
- Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer.Journal of Clinical Oncology, 1997
- New data on the pharmacokinetics of adriamycin and its major metabolite, adriamycinolEuropean Journal of Drug Metabolism and Pharmacokinetics, 1991